Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNC-TNFalpha oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Université d'Angers
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Topical, Oral
01
Overview
LNC-TNFalpha oligonucleotide is an experimental therapeutic formulation consisting of a lipid nanocapsule (LNC) delivery system loaded with an oligonucleotide, typically a small interfering RNA (siRNA), designed to silence the expression of Tumor Necrosis Factor-alpha (TNF-α). The LNC platform, characterized by a lipophilic core and a surfactant shell, provides a stable environment for the fragile genetic material, protecting it from nuclease-mediated degradation and facilitating intracellular delivery. By targeting the mRNA of TNF-α, the drug inhibits the production of this key pro-inflammatory cytokine, which plays a central role in the pathogenesis of various autoimmune and inflammatory disorders. Preclinical studies have explored its application in treating conditions such as inflammatory bowel disease (IBD) and skin inflammation, demonstrating its potential to modulate immune responses locally or systemically.
- Other names
- Lipid nanocapsule-encapsulated TNF-alpha siRNATNF-alpha siRNA lipid nanocapsulesLNC-TNFalpha siRNA
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on LNC-TNFalpha oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNC-TNFalpha oligonucleotide.